Related Experiment Video
Updated: Apr 6, 2026
04:57
Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
11.0K
Predicting survival using clinical risk scores and non-HLA immunogenetics
Y Balavarca1, K Pearce2, J Norden2
1Department of Genetic Epidemiology, University Medical Center, Göttingen, Germany.
Bone Marrow Transplantation
|July 28, 2015
Summary
Non-HLA gene polymorphisms significantly impact allogeneic hematopoietic stem cell transplantation (HSCT) survival. Adding genetic data to clinical scores improves transplant outcome prediction, highlighting the importance of pre-transplant genotyping.
Area of Science:
- Immunogenetics
- Transplantation Science
- Genomic Medicine
Background:
- Previous studies indicated non-histocompatibility leukocyte antigen (non-HLA) single-nucleotide polymorphisms (SNPs) affect outcomes in specific allogeneic hematopoietic stem cell transplantation (HSCT) subgroups.
- The clinical utility of these genetic markers in broader HSCT populations requires further elucidation.
Purpose of the Study:
- To investigate the association of 26 non-HLA polymorphisms in 16 genes with overall survival in a large cohort of 762 HSCT patients.
- To assess the added value of non-HLA polymorphisms to the established European Group for Blood and Marrow Transplantation (EBMT) risk score for predicting HSCT outcomes.
Main Methods:
- Genotyping of 26 non-HLA polymorphisms in 762 HSCT patients.
- Statistical analysis using Cox regression models, incorporating the EBMT score and individual polymorphisms.
- Evaluation of the predictive capability of a combined EBMT-genetic score.
Main Results:
- Three polymorphisms (rs8177374 in MAL, rs9340799 in ESR, rs1800795 in IL-6) were associated with reduced overall survival (P=0.026, P=0.003, P=0.007, respectively).
- A protective effect was observed for the IL-10 haplo-genotype (ACC/ACC) (P=0.02).
- The combined EBMT-genetic score improved risk group discrimination and prediction capability by 10.8% compared to the EBMT score alone.
Conclusions:
- Non-HLA polymorphisms are significant predictors of overall survival following allogeneic HSCT.
- Integrating non-HLA genetic data with clinical scores enhances the accuracy of HSCT outcome prediction.
- Pre-transplant non-HLA genotyping is crucial for optimizing risk stratification and patient management in HSCT.
Related Concept Videos
01:21Cancer Survival Analysis
838
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
838
01:20Comparing the Survival Analysis of Two or More Groups
711
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
711
01:24Kaplan-Meier Approach
743
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
743